FDA Links Philips Lumify Ultrasound Bug to Four Deaths

FDA issued an early alert on 9 October 2026 for Philips' Lumify handheld ultrasound system, describing a software fault that can block scanning at the exact moment a clinician needs it most. The app can fail to recognize a transducer it had already registered and demand re-registration without warning — a step that itself requires Wi-Fi or cellular connectivity. FDA and Philips tie the issue to four deaths and eight serious injuries, concentrated in pre-hospital and field settings where that connectivity is least reliable.

Why an early alert, not a recall

FDA's medical device recalls and early-alerts page distinguishes the two: an early alert shares safety information before a manufacturer completes the formal recall process, so clinicians and risk managers can act sooner rather than wait for a classified recall notice to post. That is the posting mechanism here. It does not mean the underlying issue is minor — FDA's early alert cites four deaths and eight serious injuries — only that the agency judged the safety information urgent enough to publish ahead of, and independent of, whatever recall classification eventually follows.

A connectivity dependency built into a point-of-care device

Lumify is built around a software-first design: the transducer is a relatively dumb peripheral, and the Android or iOS app running on a connected phone or tablet does the image processing and, evidently, transducer registration logic. That architecture is part of what makes Lumify portable and inexpensive next to a traditional cart-based ultrasound system. It also means a software fault in the registration logic becomes a hardware-unavailability problem, and the fix — re-registering the transducer — itself depends on the one resource that is scarcest exactly where point-of-care ultrasound is most valuable: ambulances, rural clinics and other field settings with inconsistent Wi-Fi or cellular coverage. Philips' own interim guidance makes that dependency explicit: use Lumify only where a signal is readily available, or keep a backup device on hand.

What happens next

Philips says it is developing a software update to resolve the registration fault and notified affected customers directly on 24 September 2026, ahead of FDA's 9 October early alert. Facilities and EMS operators running an affected iOS or Android version should review FDA's alert directly for the complete list of affected software and Philips' recommended interim precautions, and should report any similar malfunction through FDA's MedWatch program. Regulatory News will update this story if FDA assigns a formal recall classification or Philips publishes the software fix.

Frequently asked questions

What is the problem with Philips Lumify?

The Lumify Android or iOS app can fail to recognize a transducer it had already registered, then prompt the user to re-register it before scanning can resume. Re-registration requires Wi-Fi or cellular connectivity, which is not always available where Lumify is used.

What harm has FDA reported?

FDA's 9 October 2026 early alert describes reports of 4 deaths and 8 serious injuries, as of 29 September 2026, in which the unexpected re-registration event blocked scanning and delayed care, most acutely in pre-hospital settings.

Which Lumify versions are affected?

FDA's alert covers Lumify iOS software versions 2.X, 5.0, 5.1.2 and 5.1.3, and Android versions 1.X, 3.X, 4.X, 5.1 and 5.1.1.

What should Lumify users do now?

Philips advises using Lumify only where Wi-Fi or cellular signal is readily available, unless a backup ultrasound device is immediately on hand, while it develops a software update.